This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. Recent advances in drug therapy (including evolving and controversial data) for adult intensive care unit patients will be reviewed and assessed in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Zachariah Thomas, PharmD at zachariah.thomas@gmail.com or Sandra Kane-Gill, PharmD, MSc, at kanesl@upmc.edu.
BroderickJ., ConnollyS., FeldmannE.. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Circulation.2007;116(16): e391–e413.
3.
WeimarC., KurthT., KraywinkelK.. Assessment of functioning and disability after ischemic stroke. Stroke.2002; 33(8): 2053–2059.
4.
WooD., HaverbuschM., SekarP.. Effect of untreated hypertension on hemorrhagic stroke. Stroke.2004; 35(7): 1703–1708.
5.
SturgeonJ.D., FolsomA.R., LongstrethW.T.Jr. Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke.2007; 38(10): 2718–2725.
6.
HartR.G., BoopB.S., AndersonD.C.Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke.1995; 26(8): 1471–1477.
7.
RosandJ., HylekE.M., O'DonnellH.C., GreenbergS.M.Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology.2000; 55(7): 947–951.
8.
HartR.G.What causes intracerebral hemorrhage during warfarin therapy?Neurology.2000; 55(7): 907–908.
9.
DavisS.M., BroderickJ., HennericiM.. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology.2006; 66(8): 1175–1181.
10.
BroderickJ.P., BrottT.G., DuldnerJ.E., TomsickT., HusterG.Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke.1993; 24(7): 987–993.
FlibotteJ.J., HaganN., O'DonnellJ., GreenbergS.M., RosandJ.Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology.2004; 63(6): 1059–1064.
13.
BrottT., BroderickJ., KothariR.. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke.1997; 28(1): 1–5.
14.
FujiiY., TakeuchiS., SasakiO., MinakawaT., TanakaR.Multivariate analysis of predictors of hematoma enlargement in spontaneous intracerebral hemorrhage. Stroke.1998; 29(6): 1160–1166.
15.
KazuiS., MinematsuK., YamamotoH.. Predisposing factors to enlargement of spontaneous intracerebral hematoma. Stroke.1997; 28(12): 2370–2375.
16.
MayerS.A., RinconF.Treatment of intracerebral haemorrhage. Lancet Neurol.2005; 4(10): 662–672.
17.
van SwietenJ.C., KoudstaalP.J., VisserM.C., SchoutenH.J., van GijnJ.Interobserver agreement for the assessment of handicap in stroke patients. Stroke.1988; 19(5): 604–607.
18.
BanksJ.L., MarottaC.A.Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke.2007; 38(3): 1091–1096.
19.
MayerS.A.Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke.2003; 34(1): 224–229.
CasselsC.XVI European Stroke Conference. FAST Trial Shows No Benefit of Factor VII in Treatment of ICH. http://www.medscape.com/viewarticle/557558. Accessed December 19, 2007.
29.
PernegerT.V.What's wrong with Bonferroni adjustments. BMJ.1998; 316(7139): 1236–1238.
30.
Curran-EverettD.Multiple comparisons: philosophies and illustrations. Am J Physiol Regul Integr Comp Physiol.2000; 279(1): R1–R8.
31.
IoannidisJ.P.Contradicted and initially stronger effects in highly cited clinical research. JAMA.2005; 294(2): 218–228.
32.
SuggR.M., GonzalesN.R., MatherneD.E.. Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa. Neurology.2006; 67(6): 1053–1055.
33.
O'ConnellK.A., WoodJ.J., WiseR.P., LozierJ.N., BraunM.M.Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA.2006; 295(3): 293–298.
34.
DzikW.H.Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII. J Intensive Care Med.2006; 21(1): 54–59.
35.
CarterB.L., ElliottW.J.The role of pharmacists in the detection, management, and control of hypertension: a national call to action. Pharmacotherapy.2000; 20(2): 119–122.
36.
Von MuensterS.J., CarterB.L., WeberC.A.. Description of pharmacist interventions during physician-pharmacist co-management of hypertension. Pharm World Sci.2008; 30(1): 128–135.
